Emerald Bioscience Provides Corporate Update
30. September 2020 08:30 ET
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection...
Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
03. September 2020 11:39 ET
|
Emerald Bioscience, Inc.
San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...
Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of Directors
13. August 2020 08:30 ET
|
Emerald Bioscience, Inc.
San Diego, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of...
Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO
10. August 2020 08:30 ET
|
Emerald Bioscience, Inc.
Renewed team and capital focused on advancing lead compound for glaucoma into clinical development San Diego, Calif, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI)...
Emerald Bioscience Raises approximately $7.0 Million in Upsized Registered Offering
04. August 2020 18:32 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering
31. Juli 2020 09:20 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address...
Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting
09. Juni 2020 09:37 ET
|
Emerald Bioscience, Inc.
Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of...
Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in Japan
02. Juni 2020 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications,...
Emerald Bioscience Joins Alliance for Biosecurity
08. April 2020 08:30 ET
|
Emerald Bioscience, Inc.
The Alliance is a government-industry consortium that is a leading voice on biosecurity issues in the United States Long Beach, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience,...
Emerald Bioscience Announces Notice of Allowance from United States Patent Office for Proprietary Analog of Cannabidiol
09. März 2020 08:30 ET
|
Emerald Bioscience, Inc.
Long Beach, California, March 09, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI”), focused on the development of cannabinoid-based therapeutics to address global medical...